MMJ International Holdings New FDA Multiple Sclerosis Study Pushes Cannabis Components Closer To FDA Approval

RESTON, Va., June 11, 2018 /PRNewswire-PRWeb/ — MMJ International Holding’s, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research, announced today MMJ’s filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s THC/CBD pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS).

Dr. Bianca Weinstock-Guttman is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients. MMJ BioScience’s will be providing new evidence regarding clinical outcomes leading to commercial success in the scientific process of MMJ BioScience’s first pharmaceutical (THC) cannabidiol (CBD) derived medicine.

MMJ’s first clinical trial of cannabis-based medicines involving patients suffering from Multiple

... read more at: https://www.benzinga.com/pressreleases/18/06/r11857295/mmj-international-holdings-new-fda-multiple-sclerosis-study-pushes-can

Leave a Reply

Your email address will not be published. Required fields are marked *